JSC Pharmstandard

Founded in 2003, JSC Pharmstandard has solidified its position as Russia's leading pharmaceutical manufacturer, driven by a mission to ensure the availability of affordable, high-quality medicines. Its strategy is built on massive-scale generic drug production, a broad portfolio covering over 30 dosage forms, and active support of national healthcare priorities, including import substitution. Recent partnerships with academic institutions and innovation camps underscore its focus on technological modernization within the generics and biosimilars space to maintain market leadership.

Large-scale, GMP-certified manufacturing infrastructure focused on cost-effective production of generic drugs, complemented by partnerships for process innovation and development of novel formulations and biosimilars.

Pharmstandard competes primarily with other large Russian generics holdings (e.g., R-Pharm, Geropharm) for government contracts and market share. Its advantages are unmatched production scale, the broadest product portfolio, and deep alignment with national healthcare strategy, though it faces the challenge of moving up the value chain against both domestic and multinational players.